Beida pharmaceutical: the three shareholders intend to reduce the shares of the company no more than 2.31%
Beida pharmaceutical announced that the company's shareholders Beicheng investment, Yinxiang Wang and fenlai Tansheng plan to reduce the shares of the company by centralized bidding within six months after 3 trading days from the date of disclosure of this announcement (accounting for 2.31% of the total share capital of the company).
This text is a result of machine translation.
Related companies：
Briefing Feb 21, 2023 11:10 AM
· Healthcare
We-Linking Raised Over CNY 10 Mn in Angel Round
In-depth
Healthcare
IntoCare Zhang Hui: Ingenuity Forges Quality, Continuous Improvement Safeguards Lives
In 2024, nearly all medical enterprises are exploring overseas markets. This trend is driven by an anti-corruption wave within the medical industry, the demand for financing and initial public offerings, as well as challenges such as excess production capacity. Presently, venturing abroad has become an essential developmental path for medical device enterprises. Successfully entering foreign markets is not only a crucial means for the medical industry to achieve a second grow
May 09, 2024 12:18 PM
Nov 16, 2022 05:19 PM
Nov 07, 2022 04:27 PM
Aug 29, 2022 05:45 PM
Apr 18, 2022 06:30 PM
Briefing Nov 29, 2021 07:59 PM
· Healthcare
Boten Co., Ltd.: direnavir API has passed who PQ certification
Briefing Aug 31, 2021 08:59 PM
TECO shares: obtained an invention patent certificate
Healthcare
China's First Modified New Drug of Docetaxel Successfully Went to the US
Feb 19, 2025 10:41 AM
Briefing Jul 07, 2021 03:24 PM
· Healthcare
The first bank of China fund to release its second Quarterly Report
See more
Read next
Insight
In-depth
Consumer Staples · Analysis
China’s “Dark Cuisine” and Southeast Asia’s Wealth Code
Apr 07, 2025 03:46 PM
Insight
In-depth
Insight
In-depth
